Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Treme climbs a new mountain
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
ISTH 2021 – Blackstone’s Novartis spin-out scores
Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
Bergenbio dream lives on, despite Genmab's broken Axl
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
Long term forecasts confirm Keytruda’s dominance
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
